文献速递头颈外科

老年头颈癌放疗患者全身治疗现状与未来

Current State and Future of Systemic Treatment for Elderly Patients With Head and Neck Cancer Undergoing Radiotherapy.
PubMed 文献 · Head Neck · 2026-06-17

综述评估老年头颈鳞癌(HNSCC)放疗联合全身治疗的研究,纳入35项研究。适形老年患者中顺铂同步放化疗最有效且可耐受,不适合者用西妥昔单抗和卡铂结果不一;辅助治疗证据有限,免疫检查点抑制剂可行安全但需进一步研究。

要点

  • 老年HNSCC全身治疗决策应基于综合老年评估而非仅年龄。
  • 适形老年患者中顺铂同步放化疗仍为关键治疗。
  • 不适合患者中西妥昔单抗和卡铂替代结果不一。

核心结论

  • HNSCC全身治疗决策应依赖综合老年评估,不应仅凭年龄。
  • 适形老年患者中顺铂同步放化疗仍是关键治疗,但因研究异质性需谨慎考虑。

研究设计与样本

  • 综述主要数据库研究,关键词包括老年、HNSCC、全身治疗、化疗、免疫检查点抑制剂和靶向治疗。
  • 纳入65岁及以上接受根治性或辅助放疗联合全身治疗的HNSCC患者研究,共35项。

主要发现

  • 根治性治疗中,同步放化疗改善适形老年患者生存,顺铂方案最有效且可耐受。
  • 不适合患者中,西妥昔单抗和卡铂等替代方案结果不一。
  • 辅助治疗中证据有限。
  • 加入免疫检查点抑制剂看似可行且安全,但需进一步研究评估疗效和识别生物标志物。

临床怎么用

  • 对适形老年HNSCC患者可考虑顺铂同步放化疗,但需综合老年评估并注意研究异质性。
  • 不适合患者可探索西妥昔单抗或卡铂等替代,但疗效不确定。
  • 免疫检查点抑制剂在老年患者中可行安全,但疗效和生物标志物待研究。

局限性

  • 老年人群在试验中代表性不足,治疗指南有限。
  • 研究异质性影响顺铂同步放化疗的谨慎使用。
  • 辅助治疗证据有限。
  • 免疫检查点抑制剂需进一步研究评估疗效和生物标志物。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Head and neck squamous cell carcinoma (HNSCC) affects many older individuals, with over half diagnosed at 65 or older. This group is often underrepresented in trials, leading to limited treatment guidelines. This review assesses systemic treatment options, including chemotherapy, targeted therapy, and immune checkpoint inhibitors (ICIs) in elderly HNSCC patients undergoing radiotherapy. METHODS: We reviewed studies from major databases using keywords like elderly, HNSCC, systemic therapy, chemotherapy, ICI, and targeted therapy. We included studies of patients 65+ with HNSCC receiving definitive or adjuvant radiotherapy with systemic treatment. RESULTS: The review included 35 studies. In definitive treatment, concurrent chemoradiation (CRT) improved survival in fit elderly patients, with cisplatin-based CRT being most effective and tolerable. For unfit patients, alternatives like cetuximab and carboplatin have been explored, but results have varied. In the adjuvant setting, evidence is limited. Adding ICIs appears to be feasible and safe; however, it needs further research to evaluate efficacy and identify potential biomarkers. CONCLUSION: Systemic treatment decisions in HNSCC should rely on a comprehensive geriatric assessment, not age alone. For fit elderly patients, cisplatin-based CRT remains key in treatment, but its use should be cautiously considered due to study heterogeneity.

来源:Head Neck,查看原文。版权归原作者所有。

引用

  1. Zamani P, Barootchi E, Abyaneh R, et al. Current State and Future of Systemic Treatment for Elderly Patients With Head and Neck Cancer Undergoing Radiotherapy. Head Neck. 2026. PMID: 42310965. doi:10.1002/hed.70357

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。